ADAbdallah Dalabih

Abdallah Dalabih

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Abdallah Dalabih has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Intravenous Bronchodilators in Pediatric Critical Asthma: A Systematic Review and Network Meta‐Analysis

    by Samer Abu‐Sultaneh, Andrew G. Miller, Sangita Basnet, Hannah J. Craven, Abdallah Dalabih, Jose Enrique Irazuzta, Christine A. Kapuscinski, Christopher J. L. Newth, Sana J. Said, Elizabeth C. Whipple, et al.

    Introduction: Pediatric critical asthma is one of the most common pediatric illnesses in children admitted to the pediatric ward and pediatric intensive care unit (PICU). Adjunct intravenous (IV) bronchodilators are often used when initial management with systemic corticosteroids and inhaled short‐acting beta agonists (SABA) fail to provide improvement in a patient's clinical condition. While the recent guidelines gave recommendations for the use of different IV bronchodilators compared to placebo, it did not include ranking on which one should be used as first‐line or second‐line agent. The aim of this network meta‐analysis is to determine the effect of IV bronchodilators on patient‐centered outcomes and rank medications based on their effectiveness in these outcomes. Methods: A systematic review was conducted using three databases MEDLINE, Embase, and CINAHL to identify randomized control trials examining the use of IV magnesium sulfate (MgSO 4 ), IV methylxanthines (aminophylline or theophylline), IV SABA (salbutamol, terbutaline) in pediatric critical asthma patients. Bayesian network metanalytic framework was used to compare the interventions. Results are reported as odds ratio (OR) or mean difference (MD) and 95% Credible Interval (CrI). Results: Twelve trials ( n = 852) were included in the network meta‐analysis. Largest reduction in hospital length of stay (LOS), PICU admission, and PICU LOS were noted with IV MgSO 4 ; (MD: −3.1 days, 95% CrI: −6.9 days to 0.13 days), (OR 0.21; 95% CrI 0.02, 1.3), and (MD: −4.0 days, 95% CrI: −7.1 days to −1.2 days) respectively. IV MgSO 4 was ranked first in three outcomes of interest with Surface Under the Cumulative Ranking curve (SUCRA) of 0.884 for hospital LOS, 0.919 for PICU admission, and 0.957 for PICU LOS. For preventing intubation, IV SABA was ranked the highest (SUCRA 0.995), but the only study with IV SABA had zero intubation events. In a sensitivity analysis that excluded studies with zero events, the intubation rate was lowest with IV MgSO 4 (OR 0.10; 95% CrI 0.003, 0.88) and it was ranked the best treatment (SUCRA 0.921). Conclusions: In this network meta‐analysis comparing different IV adjunct bronchodilators, IV MgSO 4 was ranked first followed by IV SABA, and then IV methylxanthines. Given these findings and the favorable safety profile, ease of use, and low cost, IV MgSO 4 appears most promising the first adjunct IV bronchodilator, however, further large high‐quality trials are still needed before it can be endorsed as routine first‐line agent.


  • AARC and PALISI Clinical Practice Guideline: Pediatric Critical Asthma

    by Benjamin R. White, Andrew G. Miller, Joyce Baker, Sangita Basnet, Christopher L. Carroll, Hannah Craven, Abdallah Dalabih, Anne M. Fitzpatrick, Joel Glogowski, Jose Enrique Irazuzta, et al.

    To address the lack of guidance for clinicians in their care of children with critical asthma, a multidisciplinary team of medical providers used Grading of Recommendations, Assessment, Development, and Evaluation methodology to make the following recommendations: 1. We suggest the use of continuous inhaled short-acting β agonist (SABA) over frequent intermittent SABA in children treated for critical asthma. (Conditional recommendation, very low certainty of evidence) 2. We suggest the use of either high- or low-dose continuous inhaled SABA regimens in children treated for critical asthma. (Conditional recommendation, very low certainty of evidence) 3. We suggest the use of either dexamethasone or methylprednisolone (or an equivalent dose of prednisone/prednisolone) for children treated for critical asthma. (Conditional recommendation, very low certainty of evidence) 4. We suggest the use of intravenous (IV) magnesium (intermittent or continuous) as an adjunct therapy in children treated for critical asthma. (Conditional recommendation, low certainty of evidence) 5. We cannot recommend for or against the use of IV methylxanthines as an adjunct therapy in children treated for critical asthma. (Conditional recommendation, very low certainty of evidence) 6. We suggest the use of an IV SABA infusion as an adjunct therapy in children treated for critical asthma. (Conditional recommendation, low certainty of evidence) 7. We cannot recommend for or against the application of high-flow nasal cannula versus conventional oxygen therapy in children presenting with critical asthma with persistent hypoxemia and/or respiratory distress. (Conditional recommendation, very low certainty of evidence) 8. We suggest the use of bi-level positive airway pressure over conventional oxygen therapy in children presenting with critical asthma with persistent hypoxemia and/or respiratory distress. (Conditional recommendation, very low certainty of evidence) 9. We cannot recommend for or against the application of bi-level positive airway pressure over high-flow nasal cannula for children hospitalized with critical asthma with persistent hypoxemia and/or respiratory distress. (Conditional recommendation, very low certainty of evidence) 10. We cannot recommend for or against the application of heliox in children treated for critical asthma. (Conditional recommendation, very low certainty of evidence) 11. We suggest the use of a dedicated protocol or pathway for managing children treated for critical asthma. (Conditional recommendation, low certainty of evidence)


  • Predicting Duration of Invasive Mechanical Ventilation in Pediatric ICUs

    by Abdallah Dalabih, Salim Aljababri

  • Open Access

    An unexpected complication of prophylactic enoxaparin in an adolescent female

    by Abdallah Dalabih, Sarah Sylvester, Anna M Onisei, Claire Foster, Erin Bennett


  • Employment Opportunities for Pediatric Critical Care Fellowship Trained Physicians in the United States

    by Abdallah R. Dalabih, Parthak Prodhan, Zena L. Harris, Meredith F. Bone

    Pediatric Critical Care Medicine (PCCM) training programs and trained fellows in the United State increased steadily without a corresponding increase in population growth. PCCM trainees worry about limited employment prospects. This study aimed to quantify the demand for PCCM trained physicians in the United States by prospectively tracking full-time employment opportunities over 12 months. The number of advertised opportunities identified was low compared with number of fellows likely to be seeking jobs during same time period. If market demand remains stable, there is risk of excess supply if number of newly fellowship-trained PCCM physicians continues to rise.


  • SARS-CoV-2 Prevention Measures Concomitantly Attenuate Methicillin-Resistant Staphylococcus aureus Infection Rates

    by Abdallah Dalabih, Heather L. Young, Rachel A. Frenner, Michael H. Stroud, Bobby L. Boyanton


  • The COVID-19 pandemic and pediatric mental health: advocating for improved access and recognition

    by Abdallah Dalabih, Erin Bennett, Joyce R. Javier, On Behalf Of The Pediatric Policy Council, Shetal Shah, Jean Raphael, Mona Patel, Jonathan Davis, DeWayne Pursley, Tina Cheng, et al.

    Pediatric mental health has been poorly addressed and access to quality psychiatric care is limited in many countries around the world including wealthy nations. The novel coronavirus disease 2019 (COVID-19) pandemic caused a strain on pediatric mental health resources across the globe. This was primarily due to the stress of lockdowns, loss of caregivers, and school interruptions, which further exacerbated the mental health needs of children. Despite their unreadiness, emergency departments have been utilized to address those needs. Kostopoulou et al. reported that, although emergency departments’ pediatric visits have decreased earlier during the pandemic, mental health visits increased during the same period.


  • Comparison of Deep Sedation Regimens for Children Undergoing Elective Lumbar Puncture

    by Ryan W. Steele, Abdallah Dalabih, David P. Fitzgerald, Stephen M. Schexnayder


  • Is Orally Administered Pentobarbital a Safe and Effective Alternative to Chloral Hydrate for Pediatric Procedural Sedation?

    by Jordan Anderson, Sevilay Dalabih, Esma Birisi, Abdallah Dalabih

    OBJECTIVES Chloral hydrate had been extensively used for children undergoing sedation for imaging studies, but after the manufacturer discontinued production, pediatric sedation providers explored alternative sedation medications. Those medications needed to be at least as safe and as effective as chloral hydrate. In this study, we examined if pentobarbital is a suitable replacement for chloral hydrate. METHODS Subjects who received pentobarbital were recruited from a prospectively collected database, whereas we used a retrospective chart review to study subjects who received chloral hydrate. Sedation success was defined as the ability to provide adequate sedation using a single medication. We included electively performed sedations for subjects aged 2 months to 3 years who received either pentobarbital or chloral hydrate orally. We excluded subjects stratified as American Academy of Anesthesiologists category III or higher and those who received sedation for electroencephalogram. The data collected captured subject demographics and complications. RESULTS Five hundred thirty-four subjects were included in the final analysis, 368 in the chloral hydrate group and 166 in the pentobarbital group. Subjects who received pentobarbital had a statistically significant higher success rate [136 (82%) vs 238 (65%), p < 0.001], but longer sleeping time (18.1% vs 0%, p < 0.001) in all age groups. Subjects who received chloral hydrate had a higher risk of airway complications in the CONCLUSIONS For pediatric patients younger than 3 years of age undergoing sedation for imaging studies, oral pentobarbital may be at least as effective and as safe as chloral hydrate, making it an acceptable and practical alternative.